Developer docs
API playgroundTry for free, no card

Search company profiles

GenomeKey

Full company profile

uuid0002txl

Namestring
GenomeKey
Legal namestring
Genomic Labs Ltd.
Websiteurl
genomekey.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

GenomeKey (operating as Genomic Labs Ltd.) is a Bristol, UK-based diagnostics company founded in 2019 that is developing a next-generation in vitro diagnostic (IVD) device for the rapid identification of bacterial pathogens and their antimicrobial resistance (AMR) profiles directly from patient blood. The company's flagship product, GenomeKeyDx, is a benchtop automated device designed to detect bacteria in two hours, identify species within three hours, and deliver a full AMR profile in five hours — a turnaround compression from the 2-3 day standard for blood culture-based diagnostics and an attempt to address the fact that one in three sepsis deaths occur before current test results return. GenomeKey's underlying technology combines a proprietary bacterial DNA extraction process (reportedly shifting the human-to-bacterial DNA ratio from 2 billion:1 to 1:1) with whole genome sequencing — sourced via a core partnership with Oxford Nanopore Technologies — and proprietary machine learning algorithms for genome interpretation and AMR prediction.

The company operates two product lines: the GenomeKeyDx IVD device, currently in prototype/development and targeting CE marking, aimed at hospital emergency departments, ICUs, and clinical microbiology laboratories; and the GenomeKey Platform, a cloud-based bioinformatics SaaS available globally with freemium, Premium (£500/user/month), and Ultimate (custom) tiers. Go-to-market centers on enterprise field sales into NHS Trusts in the UK for clinical evaluations (currently active across two NHS sites), with stated global ambitions but no disclosed commercial revenues. Underlying sequencing is enabled by Oxford Nanopore's real-time, long-read platform, and compute/ecosystem support is supplemented through the NVIDIA Inception program.

GenomeKey's revenue model is bifurcated between (a) a self-serve SaaS bioinformatics platform with disclosed tiered pricing and (b) future hardware sales of the GenomeKeyDx device, where the company has signaled comparable per-test economics to existing UK sepsis tests (£100–£120 per test). To date, the company has not disclosed commercial revenue; its funding is dominated by non-dilutive grants, including a US$11.4M CARB-X award in 2024 to build an automated prototype, an earlier CARB-X award of US$3M in 2021, and support from InnovateUK. The company employs approximately 30 people across science, engineering, machine learning, and operations, and appointed diagnostics-industry veteran Randy Pritchard (former Roche Diagnostics SVP and ex-CEO/Board Member of Pillar Biosciences) as Chair of the Board in December 2024.

Short descriptiontext

GenomeKey is a Bristol-based diagnostics company building an automated IVD device and cloud bioinformatics platform that use whole genome sequencing and machine learning to identify bacterial pathogens and AMR profiles from patient blood in hours, targeting hospitals and NHS Trusts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, sepsis diagnostics, antimicrobial resistance testing, bacterial identification, clinical bioinformatics
Industry4 codes
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Analytical Laboratory Instrument Manufacturing334516
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
  • Services-Medical Laboratories8071
Product category
In Vitro Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1GenomeKeyDx IVD Device Sales
TypeHardware Sales
Description

Revenue from sale of the next-generation in vitro diagnostic device for bacterial identification and AMR profiling in hospitals and healthcare settings. Currently in development with prototype phase.

genomekey.com
2GenomeKey Platform Software
TypeSubscription Recurring
Description

Cloud-based bioinformatics platform with tiered pricing (Free, Premium £500/user/month, Ultimate custom pricing). Free tier for industrial and healthcare users with valid AST results; Premium and Ultimate tiers for scalable bioinformatics, automatic reports, and sequencing support.

genomekey.com
3R&D and Clinical Partnership Funding
TypeLicensing Royalties
Description

Non-dilutive funding from partnerships such as CARB-X (US$11.4M award) and InnovateUK for product development and clinical validation.

genomekey.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details4 tiers
1Free tier - Free forever for industrial and healthcare users
ModelFreemiumBilling cadenceMonthly
Notes

No credit card required. Available when uploading a valid AST result.

genomekey.com
2Premium tier - £500 per user per month
ModelSubscriptionBilling cadenceMonthly
Notes

Scalable bioinformatics, automatic reports, suitable for small and medium projects. Billed monthly.

genomekey.com
3Ultimate tier - Custom pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Unlimited samples, bespoke reports, and sequencing support. Contact sales for pricing.

genomekey.com
4IVD Device Test Cost
ModelUnit PricingBilling cadencePay-as-you-go
Notes

UK hospitals currently spend £100-£120 on each sepsis test. GenomeKey expects comparable cost for their test, with major savings from reduced ICU stays and better patient outcomes.

genomekey.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GenomeKey develops the GenomeKeyDx, a next-generation in vitro diagnostic (IVD) device that performs whole genome sequencing and machine-learning-based interpretation directly from patient blood to detect bacteria, identify species, and deliver a full antimicrobial resistance (AMR) profile in hours rather than days. The company also operates the GenomeKey Platform, a cloud-based bioinformatics SaaS offering tiered automated bacterial identification and AMR analysis for labs and industrial users.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Bacterial detection time reduced from 2-3 days to 2 hours
+4 more records
Product overview1 text field

GenomeKey offers two interconnected products: GenomeKeyDx, a benchtop IVD device, and the GenomeKey Platform, a software bioinformatics solution. The IVD device performs bacterial DNA extraction and whole genome sequencing directly from patient blood, while the platform provides automated analysis and reporting for labs uploading AST results. Both products leverage machine learning for species identification and AMR profiling to enable targeted antibiotic treatment within hours.

Product and service2 records
1GenomeKeyDx
CategoryIn Vitro Diagnostics (Sepsis / AMR)
Description

Next-generation in vitro diagnostic (IVD) device that detects bacteria, identifies species, and provides a full antimicrobial resistance (AMR) profile directly from patient blood in hours rather than days, using proprietary DNA extraction and machine-learning interpretation. Intended for hospital clinical microbiology labs, emergency departments and ICUs treating sepsis patients.

2GenomeKey Platform
CategoryClinical Bioinformatics Software
Description

Cloud-based bioinformatics SaaS that performs automated bacterial identification and antimicrobial resistance analysis, with tiered pricing for industrial and healthcare users uploading valid AST results. Generates automatic reports and offers bespoke reporting and sequencing support on enterprise tiers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

GenomeKey works closely with the NHS to ensure technology is designed with end-user needs in mind. Through NHS partners, the company is able to trial and evaluate their technology. Solutions are being evaluated across two different NHS sites.

Strategic tierSupportingTypeTechnology or Integration
Description

The NVIDIA Inception program supports GenomeKey development through access to cutting-edge technology and NVIDIA experts, opportunities to connect with venture capitalists, and co-marketing support.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

SetSquared Bristol is a business incubator and support program that supports GenomeKey to grow and succeed. They provide a range of resources and services including business development support and networking with other entrepreneurs.

4West of England Academic Health Science Network (WE-AHSN)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Part of a network of organisations that aims to improve healthcare and support innovation in the healthcare sector by providing access to expertise and healthcare institutions.

genomekey.com
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration to develop a new diagnostic tool for bloodstream infections. Oxford Nanopore's sequencing technology can analyse native DNA or RNA and sequence any length of fragment. The rich, real-time data enables rapid detection, identification, and evaluation of antimicrobial susceptibility in hours rather than days. GenomeKey receives continued support and access to latest technologies from Oxford Nanopore.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

bioMérieux's BioFire Blood Culture Identification panels are the dominant molecular sepsis diagnostic in clinical use today. Both companies target rapid bacterial identification and resistance profiling from positive blood cultures, and bioMérieux is the entrenched incumbent GenomeKey must displace or partner with for hospital adoption.

TypeEmerging player
Description

Selux Diagnostics is developing rapid phenotypic antimicrobial susceptibility testing with single-cell resolution, targeting the same AMR profiling use case as GenomeKey. Comparable early-stage positioning in the rapid AST market with hospital microbiology labs as primary customers.

TypeEmerging player
Description

Specific Diagnostics (acquired by bioMérieux) developed a rapid phenotypic AST technology based on volatile organic compound detection. Direct overlap with GenomeKey's AMR profiling goal, though using a fundamentally different detection method—useful for competitive benchmarking on speed and accuracy.

TypeBroad incumbent
Description

Cepheid's GeneXpert system is a widely deployed molecular diagnostics platform in hospitals, including for bloodstream infections. While broader in scope than GenomeKey, it competes for the same hospital capital budget and clinical microbiology workflow share, and could be a potential commercialization or acquisition partner.

TypeDirect peer
Description

Q-linea develops the ASTar system for rapid antimicrobial susceptibility testing from positive blood cultures, addressing the same clinical need as GenomeKey's AMR profiling output. Both companies compete to shorten the time from blood draw to targeted antibiotic therapy in sepsis management.

TypeBroad incumbent
Description

Roche's discontinued SeptiFast (referenced in GenomeKey's CCO background) was a direct-from-blood sepsis molecular test, and Roche remains the largest IVD incumbent with global hospital reach. Represents both a benchmark for prior attempts at rapid sepsis diagnostics and a potential global commercialization/acquisition partner.

TypeDirect peer
Description

T2 Biosystems developed T2Bacteria and T2Candida direct-from-blood molecular panels for sepsis diagnosis, the most direct comparable to GenomeKey's rapid bacterial ID from whole blood. GenomeKey's CCO Chris Brain previously led commercialization at T2, and both target the same unmet need of replacing days-long blood cultures in hospital sepsis workflows.

TypeDirect peer
Description

Accelerate Diagnostics offers the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing direct from positive blood cultures, targeting the same hours-not-days sepsis workflow that GenomeKey is building toward. Comparable use case, customer base, and hospital procurement motion.

TypeOthers
Description

Oxford Nanopore is GenomeKey's core sequencing technology partner and supplies the nanopore platform underlying the GenomeKeyDx device. While not a direct competitor in sepsis IVDs, Oxford Nanopore's own clinical diagnostics ambitions and product roadmap materially shape GenomeKey's technology trajectory and IP positioning.

TypeEmerging player
Description

Resistell (Switzerland) is developing nanomotion-based rapid antibiotic susceptibility testing direct from clinical samples, addressing the same AMR profiling opportunity as GenomeKey. Comparable early-stage Swiss/UK European diagnostics competitor with similar AMR-focused value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenomeKey

In Vitro Diagnosticsgenomekey.com

GenomeKey is a Bristol-based diagnostics company building an automated IVD device and cloud bioinformatics platform that use whole genome sequencing and machine learning to identify bacterial pathogens and AMR profiles from patient blood in hours, targeting hospitals and NHS Trusts.

What GenomeKey does

GenomeKey (operating as Genomic Labs Ltd.) is a Bristol, UK-based diagnostics company founded in 2019 that is developing a next-generation in vitro diagnostic (IVD) device for the rapid identification of bacterial pathogens and their antimicrobial resistance (AMR) profiles directly from patient blood. The company's flagship product, GenomeKeyDx, is a benchtop automated device designed to detect bacteria in two hours, identify species within three hours, and deliver a full AMR profile in five hours — a turnaround compression from the 2-3 day standard for blood culture-based diagnostics and an attempt to address the fact that one in three sepsis deaths occur before current test results return. GenomeKey's underlying technology combines a proprietary bacterial DNA extraction process (reportedly shifting the human-to-bacterial DNA ratio from 2 billion:1 to 1:1) with whole genome sequencing — sourced via a core partnership with Oxford Nanopore Technologies — and proprietary machine learning algorithms for genome interpretation and AMR prediction.

The company operates two product lines: the GenomeKeyDx IVD device, currently in prototype/development and targeting CE marking, aimed at hospital emergency departments, ICUs, and clinical microbiology laboratories; and the GenomeKey Platform, a cloud-based bioinformatics SaaS available globally with freemium, Premium (£500/user/month), and Ultimate (custom) tiers. Go-to-market centers on enterprise field sales into NHS Trusts in the UK for clinical evaluations (currently active across two NHS sites), with stated global ambitions but no disclosed commercial revenues. Underlying sequencing is enabled by Oxford Nanopore's real-time, long-read platform, and compute/ecosystem support is supplemented through the NVIDIA Inception program.

GenomeKey's revenue model is bifurcated between (a) a self-serve SaaS bioinformatics platform with disclosed tiered pricing and (b) future hardware sales of the GenomeKeyDx device, where the company has signaled comparable per-test economics to existing UK sepsis tests (£100–£120 per test). To date, the company has not disclosed commercial revenue; its funding is dominated by non-dilutive grants, including a US$11.4M CARB-X award in 2024 to build an automated prototype, an earlier CARB-X award of US$3M in 2021, and support from InnovateUK. The company employs approximately 30 people across science, engineering, machine learning, and operations, and appointed diagnostics-industry veteran Randy Pritchard (former Roche Diagnostics SVP and ex-CEO/Board Member of Pillar Biosciences) as Chair of the Board in December 2024.

GenomeKey firmographics

Firmographics
Name
GenomeKey
Legal name
Genomic Labs Ltd.
Website
https://genomekey.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
GenomeKey is a Bristol-based diagnostics company building an automated IVD device and cloud bioinformatics platform that use whole genome sequencing and machine learning to identify bacterial pathogens and AMR profiles from patient blood in hours, targeting hospitals and NHS Trusts.
Ownership category
akta.pro rank

GenomeKey industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • In vitro diagnostics
  • Sepsis diagnostics
  • Antimicrobial resistance testing
  • Bacterial identification
  • Clinical bioinformatics

Where GenomeKey is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

GenomeKey business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. GenomeKeyDx IVD Device Sales: Revenue from sale of the next-generation in vitro diagnostic device for bacterial identification and AMR profiling in hospitals and healthcare settings. Currently in development with prototype phase.
  2. GenomeKey Platform Software: Cloud-based bioinformatics platform with tiered pricing (Free, Premium £500/user/month, Ultimate custom pricing). Free tier for industrial and healthcare users with valid AST results; Premium and Ultimate tiers for scalable bioinformatics, automatic reports, and sequencing support.
  3. R&D and Clinical Partnership Funding: Non-dilutive funding from partnerships such as CARB-X (US$11.4M award) and InnovateUK for product development and clinical validation.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree tier - Free forever for industrial and healthcare users
SubscriptionMonthlyPremium tier - £500 per user per month
SubscriptionMulti-year contractUltimate tier - Custom pricing
Unit PricingPay-as-you-goIVD Device Test Cost

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

GenomeKey product offering

Product offering

Core offering

GenomeKey develops the GenomeKeyDx, a next-generation in vitro diagnostic (IVD) device that performs whole genome sequencing and machine-learning-based interpretation directly from patient blood to detect bacteria, identify species, and deliver a full antimicrobial resistance (AMR) profile in hours rather than days. The company also operates the GenomeKey Platform, a cloud-based bioinformatics SaaS offering tiered automated bacterial identification and AMR analysis for labs and industrial users.

Product overview

GenomeKey offers two interconnected products: GenomeKeyDx, a benchtop IVD device, and the GenomeKey Platform, a software bioinformatics solution. The IVD device performs bacterial DNA extraction and whole genome sequencing directly from patient blood, while the platform provides automated analysis and reporting for labs uploading AST results. Both products leverage machine learning for species identification and AMR profiling to enable targeted antibiotic treatment within hours.

Differentiator

Problem solved

Functional benefit

Products and services

  • GenomeKeyDx Next-generation in vitro diagnostic (IVD) device that detects bacteria, identifies species, and provides a full antimicrobial resistance (AMR) profile directly from patient blood in hours rather than days, using proprietary DNA extraction and machine-learning interpretation. Intended for hospital clinical microbiology labs, emergency departments and ICUs treating sepsis patients.
  • GenomeKey Platform Cloud-based bioinformatics SaaS that performs automated bacterial identification and antimicrobial resistance analysis, with tiered pricing for industrial and healthcare users uploading valid AST results. Generates automatic reports and offers bespoke reporting and sequencing support on enterprise tiers.

Quantifiable outcome

  • Bacterial detection time reduced from 2-3 days to 2 hours
  • +4 more outcomes

Companies that use GenomeKey

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

GenomeKey technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

GenomeKey partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • NHS TrustscoreStrategic or Co-development PartnerGenomeKey works closely with the NHS to ensure technology is designed with end-user needs in mind. Through NHS partners, the company is able to trial and evaluate their technology. Solutions are being evaluated across two different NHS sites.
  • NVIDIAsupportingTechnology or IntegrationThe NVIDIA Inception program supports GenomeKey development through access to cutting-edge technology and NVIDIA experts, opportunities to connect with venture capitalists, and co-marketing support.
  • SetSquared BristolsupportingStrategic or Co-development PartnerSetSquared Bristol is a business incubator and support program that supports GenomeKey to grow and succeed. They provide a range of resources and services including business development support and networking with other entrepreneurs.
  • West of England Academic Health Science Network (WE-AHSN)supportingStrategic or Co-development PartnerPart of a network of organisations that aims to improve healthcare and support innovation in the healthcare sector by providing access to expertise and healthcare institutions.
  • Oxford Nanopore TechnologiescoreTechnology or IntegrationCollaboration to develop a new diagnostic tool for bloodstream infections. Oxford Nanopore's sequencing technology can analyse native DNA or RNA and sequence any length of fragment. The rich, real-time data enables rapid detection, identification, and evaluation of antimicrobial susceptibility in hours rather than days. GenomeKey receives continued support and access to latest technologies from Oxford Nanopore.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

GenomeKey competitors and assessment

Company assessment

Direct peers

  • bioMérieux (BioFire Diagnostics): bioMérieux's BioFire Blood Culture Identification panels are the dominant molecular sepsis diagnostic in clinical use today. Both companies target rapid bacterial identification and resistance profiling from positive blood cultures, and bioMérieux is the entrenched incumbent GenomeKey must displace or partner with for hospital adoption.
  • Q-linea: Q-linea develops the ASTar system for rapid antimicrobial susceptibility testing from positive blood cultures, addressing the same clinical need as GenomeKey's AMR profiling output. Both companies compete to shorten the time from blood draw to targeted antibiotic therapy in sepsis management.
  • T2 Biosystems: T2 Biosystems developed T2Bacteria and T2Candida direct-from-blood molecular panels for sepsis diagnosis, the most direct comparable to GenomeKey's rapid bacterial ID from whole blood. GenomeKey's CCO Chris Brain previously led commercialization at T2, and both target the same unmet need of replacing days-long blood cultures in hospital sepsis workflows.
  • Accelerate Diagnostics: Accelerate Diagnostics offers the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing direct from positive blood cultures, targeting the same hours-not-days sepsis workflow that GenomeKey is building toward. Comparable use case, customer base, and hospital procurement motion.

Emerging players

  • Selux Diagnostics: Selux Diagnostics is developing rapid phenotypic antimicrobial susceptibility testing with single-cell resolution, targeting the same AMR profiling use case as GenomeKey. Comparable early-stage positioning in the rapid AST market with hospital microbiology labs as primary customers.
  • Specific Diagnostics: Specific Diagnostics (acquired by bioMérieux) developed a rapid phenotypic AST technology based on volatile organic compound detection. Direct overlap with GenomeKey's AMR profiling goal, though using a fundamentally different detection method—useful for competitive benchmarking on speed and accuracy.
  • Resistell: Resistell (Switzerland) is developing nanomotion-based rapid antibiotic susceptibility testing direct from clinical samples, addressing the same AMR profiling opportunity as GenomeKey. Comparable early-stage Swiss/UK European diagnostics competitor with similar AMR-focused value proposition.

Broad incumbents

  • Cepheid (Danaher): Cepheid's GeneXpert system is a widely deployed molecular diagnostics platform in hospitals, including for bloodstream infections. While broader in scope than GenomeKey, it competes for the same hospital capital budget and clinical microbiology workflow share, and could be a potential commercialization or acquisition partner.
  • Roche Diagnostics: Roche's discontinued SeptiFast (referenced in GenomeKey's CCO background) was a direct-from-blood sepsis molecular test, and Roche remains the largest IVD incumbent with global hospital reach. Represents both a benchmark for prior attempts at rapid sepsis diagnostics and a potential global commercialization/acquisition partner.

Others

  • Oxford Nanopore Technologies: Oxford Nanopore is GenomeKey's core sequencing technology partner and supplies the nanopore platform underlying the GenomeKeyDx device. While not a direct competitor in sepsis IVDs, Oxford Nanopore's own clinical diagnostics ambitions and product roadmap materially shape GenomeKey's technology trajectory and IP positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

GenomeKey social profiles

Digital presence

GenomeKey financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenomeKey leadership team

Management profile

Number of profiles

Profiles9 records

GenomeKey funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenomeKey M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenomeKey

What does GenomeKey do?

GenomeKey develops the GenomeKeyDx, a next-generation in vitro diagnostic (IVD) device that performs whole genome sequencing and machine-learning-based interpretation directly from patient blood to detect bacteria, identify species, and deliver a full antimicrobial resistance (AMR) profile in hours rather than days. The company also operates the GenomeKey Platform, a cloud-based bioinformatics SaaS offering tiered automated bacterial identification and AMR analysis for labs and industrial users.

Is GenomeKey a public or private company?

GenomeKey is a private company. It is classified as venture growth investor backed and is currently operating.

When was GenomeKey founded?

GenomeKey was founded in 2019. It employs 11 to 50 people.

Where is GenomeKey based?

GenomeKey is headquartered in Bristol, United Kingdom, in the Europe region.

How does GenomeKey make money?

Three revenue lines are on record. GenomeKeyDx IVD Device Sales are the primary driver. The others are genomeKey Platform Software and R&D and Clinical Partnership Funding.

Who are GenomeKey's main competitors?

Direct peers on record are bioMérieux (BioFire Diagnostics), Q-linea, T2 Biosystems and Accelerate Diagnostics. Emerging players are Selux Diagnostics, Specific Diagnostics and Resistell. Broad incumbents are Cepheid (Danaher) and Roche Diagnostics. Oxford Nanopore Technologies is listed as an others.

Does GenomeKey have an API?

No public API is recorded for GenomeKey.

What industry is GenomeKey in?

GenomeKey's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales